Dashboard Market News Pricing Contact Us
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Oncopeptides AB banner

Oncopeptides AB
STO:ONCO

Watchlist Manager
Oncopeptides AB Logo
Oncopeptides AB
STO:ONCO
Watchlist
Price: 1.62 SEK -1.22% Market Closed
Market Cap: kr617.5m
Write Note Create Alert Ask AI

Wall St Price Targets

ONCO Price Targets Summary
Oncopeptides AB

Wall Street analysts forecast ONCO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ONCO is 2.35 SEK with a low forecast of 2.02 SEK and a high forecast of 3.26 SEK.

ONCO Lowest Forecast
Wall Street Target
kr2.02
25% Upside
ONCO Average Forecast
Wall Street Target
kr2.35
45% Upside
ONCO Highest Forecast
Wall Street Target
kr3.26
101% Upside
Lowest Forecast
Price Target
2.02 SEK
25% Upside
Average Forecast
Price Target
2.35 SEK
45% Upside
Highest Forecast
Price Target
3.26 SEK
101% Upside
Oncopeptides AB Competitors:
Price Targets

Revenue
Forecast

N/A
Past Growth
73% / Year
Estimated Growth
Estimates Accuracy
-26%
Average Miss
N/A
Past Growth
73% / Year
Estimated Growth
Estimates Accuracy
-26%
Average Miss

The compound annual growth rate for Revenue over the next 3 years is 73%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
62% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss
N/A
Past Growth
62% / Year
Estimated Growth
Estimates Accuracy
-14%
Average Miss

The compound annual growth rate for Gross Profit over the next 3 years is 62%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
5%
Average Beat

What are analyst estimates?

Continue ONCO Research

Summary
ONCO intrinsic value, competitors valuation, and company profile.
DCF Valuation
ONCO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ONCO stock valuation using valuation multiples.
Wall St Estimates
ONCO price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ONCO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Oncopeptides AB listings:
F • EUR
OND
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is ONCO's stock price target?
Price Target
2.35 SEK

According to Wall Street analysts, the average 1-year price target for ONCO is 2.35 SEK with a low forecast of 2.02 SEK and a high forecast of 3.26 SEK.

What is the Revenue forecast for Oncopeptides AB?
Projected CAGR
73%

The compound annual growth rate for Revenue over the next 3 years is 73%.

What is the Gross Profit forecast for Oncopeptides AB?
Projected CAGR
62%

The compound annual growth rate for Gross Profit over the next 3 years is 62%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.